Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis.
about
Biomarkers in triple negative breast cancer: A reviewPotent anti-tumour activity of a novel conditionally replicating adenovirus for melanoma via inhibition of migration and invasion.Chromatin CKAP2, a new proliferation marker, as independent prognostic indicator in breast cancerTriple negative breast cancer in a poor resource setting in North-Western Tanzania: a preliminary study of 52 patientsPathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapySignificance of immunohistochemistry in breast cancerPredicting response and survival in chemotherapy-treated triple-negative breast cancer.Aurora-A identifies early recurrence and poor prognosis and promises a potential therapeutic target in triple negative breast cancerPulmonary Adenocarcinoma in Malignant Pleural Effusion Enriches Cancer Stem Cell Properties during Metastatic CascadeBiomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study NetworkA prognostic model for triple-negative breast cancer patients based on node status, cathepsin-D and Ki-67 index.HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy.Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer.Retrospective analysis of metastatic behaviour of breast cancer subtypesEffect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: A meta-analysis.Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile.Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging.P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients.Update on triple-negative breast cancer: prognosis and management strategiesClinical implications of proliferation activity in T1 or T2 male gastric cancer patientsHigh Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast CancerKi-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registryAn associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy.Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer.Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin.Immunohistochemical profile and morphology in triple - negative breast cancers.Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses.New insights into the prognostic value of Ki-67 labeling index in patients with triple-negative breast cancerPrognostic and predictive value of Ki-67 in triple-negative breast cancer.Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.Endocan as a prognostic biomarker of triple-negative breast cancer.Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index.Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers.A Prognostic Model for Patients with Triple-Negative Breast Cancer: Importance of the Modified Nottingham Prognostic Index and Age.The classification of invasive carcinoma of the breast.Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer.Heterogeneity of triple-negative breast cancer: mammographic, US, and MR imaging features according to androgen receptor expression.Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer.
P2860
Q26775094-F54D685A-DE31-4158-A6DF-B5CFC0DCFF86Q33613626-84090727-B3E4-4EAF-BD86-EC2262FFD285Q33699104-82D01255-92B4-45D9-94C2-1D81061741C6Q33842913-96D83234-42C0-4AEC-B30A-F39A5A757B7BQ33873330-01E54076-0218-472C-B33C-9D264B36F0C2Q34023682-FDE68AD5-BF4E-43CA-8D01-494F094B51AEQ34354538-7F2EC625-432A-4CBE-B694-79079B436022Q34599715-09E0DF73-C108-43E1-A5D1-A74CCE4BFA6BQ34712278-D3EA71E6-45EF-44E4-A41C-B546456241DEQ35054455-CC0AF84C-4C96-4B9B-B0F4-F2CA03F11824Q35067947-C330B044-91CD-4B18-BD58-40C10A87B5D0Q35175294-F96683B8-6D32-4813-9C32-194C550BC59AQ35237197-939E989A-6324-4549-BC0A-799340680EF0Q35252752-D8F32611-81A7-4A42-B913-5D761B634D19Q35759050-D27D29BF-8D51-4966-A22A-15A23D7911DEQ35928203-1810F05B-873B-4551-8A83-4F5698572426Q35941029-9AE6CFAE-D6F6-45FB-BD8C-5B30A542FDB2Q36109265-76BB18B1-CBC6-44A1-ABD0-C008E0B4890EQ36289931-97D4D50A-AF83-45BA-B9BC-D2C3EA913930Q36311616-36B855DE-488D-4A16-A450-17933F05DE66Q36356936-055A5F3A-23D7-4772-8CCB-F49F29DDD6FBQ36558409-C8B8F49F-094D-4B2B-AD34-9B2A24D6B2F2Q36892788-7AABEA89-2CCD-48D3-AE2C-701E9BC4EEB1Q36956220-46EB1AB5-ACF9-4136-97F7-056DB8D89D04Q37056923-ED30CC46-8B4A-4A01-A59B-766278D2910CQ37101590-A74362D4-692D-4EF4-AA4A-B75FC44A1536Q37111323-C54B6359-6E99-4B96-9873-14B7DF205C37Q37113312-8ED7B56A-A50F-4377-939F-B21FC7A70DA3Q37269463-5D286913-993E-4962-BCA0-BDD701F6D168Q37327661-7E232C43-FA58-4EB6-94F2-ED50670DF6F9Q37350137-3FA630F2-391D-402B-8195-2F5BD9AFF2F1Q37578395-EC1190B9-9FEE-4D2A-A8FA-B063C2440C85Q37690172-743A8B13-B192-4F99-A1F2-231EA59BDF4BQ37704344-5F389D8D-8377-4948-8900-20D9FE85357DQ37735965-2EA44734-41E6-4BDF-B7C9-7E75DD556F97Q38132239-CB96B566-D403-4379-870B-780BA474E7A6Q38250247-FE4BAEE1-6647-4EA2-90B4-140B0BDC7AEDQ38426713-C15EE035-A1F3-47B8-AB85-2888E88BA50DQ38434102-92FC0CC9-47C3-4115-B6C3-CB58CCDDCAD5Q38451966-BC6F5A5D-4DF5-4FF2-A881-40A49E9FCE78
P2860
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Ki-67 can be used for further ...... ferent response and prognosis.
@ast
Ki-67 can be used for further ...... ferent response and prognosis.
@en
type
label
Ki-67 can be used for further ...... ferent response and prognosis.
@ast
Ki-67 can be used for further ...... ferent response and prognosis.
@en
prefLabel
Ki-67 can be used for further ...... ferent response and prognosis.
@ast
Ki-67 can be used for further ...... ferent response and prognosis.
@en
P2093
P2860
P356
P1476
Ki-67 can be used for further ...... ferent response and prognosis.
@en
P2093
Bhumsuk Keam
Dae Seog Heo
Do-Youn Oh
Dong-Wan Kim
In Ae Park
Jee Hyun Kim
Kyung-Hun Lee
Sae-Won Han
Se-Hoon Lee
Seock-Ah Im
P2860
P2888
P356
10.1186/BCR2834
P577
2011-03-02T00:00:00Z
P5875
P6179
1013651553